Clinical Trials Browser

Active not recruiting × INDUSTRY × apalutamide × Clear all

NCT02257736 2026-03-19

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT02531516 2026-03-19

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04108208 2026-03-16

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Phase 4 Active not recruiting

75 enrolled 9 charts

Prostatic Neoplasms

NCT03523442 2026-03-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05901649 2026-03-13

ArtemisPRO

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT05884398 2026-03-12

LIBERTAS

Phase 3 Active not recruiting

Metastatic Castrate-sensitive Prostate Cancer

NCT04325828 2026-02-13

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT01946204 2026-02-02

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT03767244 2026-01-16

PROTEUS

Phase 3 Active not recruiting

Prostatic Neoplasms